Skip to content
Screener

Cogent Biosciences, Inc. COGT Q4 2024 Annual earnings

Reported February 25, 2025 · Before market open

EPS-$0.09Beat by $0.50
EPS estimate-$0.59

Next report

Aug 10, 2026 (In 3 days)
Revenue estimate$1.0K
EPS estimate-$0.55

Financials

Q4 2024

Income statement

See full
Operating income-$73.7M-26.6%
Net income-$67.9M-24.9%
EPS (diluted)-$0.50-233%

Balance sheet

See full
Cash & equivalents$98.2M+84.4%
Total debt$17.5M-7.4%
Total equity$256.3M-0.6%
Total assets$327.9M+4.6%

Cash flow

See full
Operating cash flow-$60.6M-37.5%
CapEx$75.0K-76.2%
Free cash flow-$60.7M-36.6%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$861.6M+70.1%
Enterprise value$780.9M+65.4%

Returns & leverage

See full
Return on equity-99.5%+48.7pp
Debt / equity0.1×0.0×
Current ratio5.3×-1.8×

FAQ

When did Cogent Biosciences, Inc. report Q4 2024 earnings?
Cogent Biosciences, Inc. (COGT) reported Q4 2024 earnings on February 25, 2025 before market open.
What were Cogent Biosciences, Inc.'s Q4 2024 revenue and EPS?
Cogent Biosciences, Inc. reported eps of $-0.09 for Q4 2024.
Did Cogent Biosciences, Inc. beat estimates in Q4 2024?
EPS beat the consensus estimate of $-0.59 by $0.50.
Where can I find Cogent Biosciences, Inc.'s Q4 2024 SEC filings?
You can read the 8-K earnings release (0000950170-25-026103) and the 10-K periodic report (0000950170-25-026115) directly on SEC EDGAR. The filing index links above go to sec.gov.